1430230-65-1

Basic information

• Product Name: trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate
• Synonyms: trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate;CarbaMic acid, N-[(3R,4S)-tetrahydro-4-hydroxy-3-furanyl]-, 1,1-diMethylethyl ester, rel-;tert-butyl N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]carbamate;tert-butyl N-[trans-4-hydroxyoxolan-3-yl]carbamate;tert-Butyl ((3R,4S)-rel-4-hydroxytetrahydrofuran-3-yl)carbamate
• CAS NO: 1430230-65-1
• Molecular Formula: C9H17NO4
• Molecular Weight: 203.23558
• Mol File: 1430230-65-1.mol

Chemical Properties

• Boiling Point: 351.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• PKA: 11.58±0.40(Predicted)
• CAS DataBase Reference: trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate(1430230-65-1)
• EPA Substance Registry System: trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate(1430230-65-1)

Safety Data

• Hazardous Substances Data: 1430230-65-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate is used as a stabilizer and antioxidant for enhancing the shelf life of pharmaceutical products. Its ability to inhibit oxidation helps maintain the integrity and potency of medications over time.
Used in Polymer Industry:
In the polymer industry, trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate serves as a crucial stabilizer and antioxidant. It protects polymers from degradation, thereby extending their durability and performance in various applications.
Used in Food Packaging Materials:
Trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate is utilized in food packaging materials to act as a preservative. It helps to prolong the shelf life of packaged foods by preventing oxidation, which can lead to spoilage and degradation of the food's quality.
Used in Therapeutic Applications:
Although still under investigation, trans-tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbaMate has shown potential therapeutic properties, particularly in the treatment of neurodegenerative diseases and cancer. Its exact role and efficacy in these applications require further research to fully understand the potential benefits and risks associated with its use.

Upstream product

• 144870-96-2 4-amino-3-hydroxytetrahydrofuran 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1430230-65-1 (±)-cis-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 103-80-0 phenylacetyl chloride 
• 190792-70-2 (3R,4S)-4-aminotetrahydrofuran-3-ol 
• 144870-96-2 trans-4-amino-3-hydroxytetrahydrofuran 
• 1708-29-8 2,5-dihydrofuran 
• 4248-19-5 tert-butyl carbazate 
• 153610-13-0 (3S,4R)-4-Azido-tetrahydro-furan-3-ol 

Downstream Products

• 153610-11-8 (3R,4R)-3-amino-4-hydroxy-tetrahydrofuran 
• 1414975-77-1 tert-butyl N-(4-oxotetrahydrofuran-3-yl)carbamate 
• 1629586-23-7 tert-butyl ((3R,4S)-4-aminotetrahydrofuran-3-yl)carbamate 
• 1430230-65-1 (3S,4S)-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 153610-11-8 (3S,4S)-3-amino-4-hydroxytetrahydrofuran 
• 1629586-23-7 tert-butyl rac-cis-N-(4-aminotetrahydrofuran-3-yl)carbamate 
• 1629586-23-7 tert-butyl ((3S,4S)-4-aminotetrahydrofuran-3-yl)carbamate 
• 1629586-23-7 C₉H₁₈N₂O₃ 

Relevant articles and documents

Scalable Syntheses of Chirally Pure Mono-protected and Orthogonally Di-protected cis -3,4-Diaminotetrahydrofurans

Scalable and chromatography-free syntheses of chirally pure and orthogonally protected cis -3,4-diaminotetrahydrofurans prepared from a single starting material, 3,4-epoxytetrahydrofuran, are presented..

SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF

Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF

There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Enzymatic preparation of cis and trans-3-amino-4-hydroxytetrahydrofurans and cis-3-amino-4-hydroxypyrrolidines

The lipase catalyzed resolution of cis and trans-3-amino-4-hydroxytetrahydrofurans and cis-3-amino-4-hydroxypyrrolidines have been studied. For all the heterocycles, the best enantioselectivity was obtained using Candida antarctica lipases A and B as cata

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.